GLP1_NEW
TERN-601 250 mg tablet once daily
TERN60_PO_250MG_QD
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.31 (0.00 to 10.71) | 0.71 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.88 (0.31 to 13.14) | 0.50 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 5.44 (1.99 to 18.04) | 0.32 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 1.89 (0.23 to 16.25) | 0.69 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.97 (0.37 to 10.83) | 0.49 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.28 (0.16 to 9.94) | 0.62 |